Conclusion: Postoperative nausea and vomiting is significantly lower in ondansetron
and dexamethasone combination group as compared to ondansetron
alone group after elective laparoscopic cholecystectomy.
The researchers found that ondansetron
exposure increased from less than 1 percent before 2000 to 13 percent in 2013 to 2014 among women in the control group.
Aprepitant, placebo identical to aprepitant, 4 mg ondansetron
and saline solution were prepared by the pharmacy department and given to the blinded investigators.
There have been two studies that have suggested an increased risk in specific major birth defects with first-trimester ondansetron
Both the drugs Ondansetron
and Granisetron had no significant effect on pulse rate and blood pressure.
Conclusion: No association of anti-emetic efficacy of ondansetron
with 18792A>G polymorphism in the target gene of 5-hydroxytryptamine type 3 subtype B was found.
The patients could request antiemetic and opioid analgesic medications, and the doses were recorded as well as the level of satisfactory reduction of PONV (0 = no symptoms; 1 = mild: few symptoms and not requiring treatment; 2 = moderate: presented symptoms and needed ondansetron
8 mg iv; 3 = severe: persisted symptoms after received ondansetron
8 mg iv and needed re-administration of ondansetron
8 mg iv).
Keywords * Ondansetron
* Hyperpigmentation * Fixed drug eruption * 5HT3 receptor antagonists
To determine whether the contaminated lots of ondansetron
harbored the same fungal strains as infected patients, we used WGST.
The active pharmaceutical ingredient in Zuplenz, ondansetron
, belongs to a class of medications called serotonin 5-HT3 receptor antagonists and works by blocking the action of serotonin, a natural substance that may cause nausea and vomiting.
When used in combination with ondansetron
and palonosetron, dexamethasone (8-11) was reported to be effective in reducing PONV.
In the United States ondansetron
is commonly used to treat NVP.